| Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. | |
| | |
MedLine Citation:
|
PMID: 9849696 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We studied pubertal status and ovarian function in 21 girls aged 11-21 years who had earlier received 1.2-13 years (median 7 years) high-dose chemotherapy and autologous BMT without TBI for malignant tumors. Ten of them were given busulfan (600 mg/m2) and melphalan (140 mg/m2) with or without cyclophosphamide (3.6 g/m2). Eleven others did not receive busulfan. Twelve girls (57%) had clinical and hormonal evidence of ovarian failure. Among nine others who had completed normal puberty, six had normal gonadotropin levels, one had elevated gonadotropin levels and two had gonadotropin levels at the upper limit of normal. The 10 girls who received busulfan all developed severe and persistent ovarian failure. High-dose busulfan is therefore a major cause of ovarian failure even when given in the prepubertal period. These findings emphasize the need for long-term endocrine follow-up of these patients in order to initiate estrogen replacement therapy. |
| | |
Authors:
|
C Teinturier; O Hartmann; D Valteau-Couanet; E Benhamou; P F Bougneres |
Related Documents
:
|
21524816 - A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluo... 2010106 - The sister (mary) joseph nodule: its significance in gynecology. 17223446 - New and emerging intraperitoneal (ip) drugs for ovarian cancer treatment. 11321496 - Primary epithelial ovarian carcinoma in taiwanese women. 17409936 - Glutathione-s-transferase p1 isoenzyme polymorphisms, platinum-based chemotherapy, and ... 16710036 - Her-2 is an independent prognostic factor in endometrial cancer: association with outco... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Bone marrow transplantation Volume: 22 ISSN: 0268-3369 ISO Abbreviation: Bone Marrow Transplant. Publication Date: 1998 Nov |
Date Detail:
|
Created Date: 1999-02-16 Completed Date: 1999-02-16 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8702459 Medline TA: Bone Marrow Transplant Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 989-94 Citation Subset: IM |
Affiliation:
|
Department of Pediatric Endocrinology, Hopital Saint-Vincent de Paul, Paris, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Antineoplastic Agents, Alkylating / adverse effects Bone Marrow Transplantation / adverse effects* Busulfan / administration & dosage, adverse effects* Child Child, Preschool Estradiol / blood Female Follicle Stimulating Hormone / blood Follow-Up Studies Humans Immunosuppressive Agents / adverse effects* Luteinizing Hormone / blood Melphalan / adverse effects Neoplasms / complications, therapy Ovarian Failure, Premature / chemically induced* Ovarian Function Tests Ovary / drug effects, physiopathology* Puberty, Delayed / chemically induced Survivors Transplantation Conditioning Transplantation, Autologous |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents, Alkylating; 0/Immunosuppressive Agents; 148-82-3/Melphalan; 50-28-2/Estradiol; 55-98-1/Busulfan; 9002-67-9/Luteinizing Hormone; 9002-68-0/Follicle Stimulating Hormone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experi...
Next Document: Late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation in children.